GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating Gilead Sciences, Inc. for potential violations of securities laws related to misleading statements and undisclosed information regarding its HIV treatment trials [1][2]. Group 1: Investigation Details - The investigation centers on whether Gilead issued false or misleading statements or failed to disclose critical information to investors [2]. - On June 10, 2025, Gilead announced that the U.S. FDA placed a clinical hold on its HIV treatment trials for GS-1720 and GS-4182 due to safety concerns, specifically a decrease in CD4+ T-cell and absolute lymphocyte counts in some trial participants [2]. Group 2: Legal Representation - The Schall Law Firm offers free consultations for shareholders who may have suffered losses and encourages them to reach out for assistance [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].